117 related articles for article (PubMed ID: 22370312)
21. On being metachromatic: mystique and misunderstanding in mastocytosis.
Gotlib J
Am J Hematol; 2009 Dec; 84(12):779-81. PubMed ID: 19899132
[No Abstract] [Full Text] [Related]
22. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
[No Abstract] [Full Text] [Related]
23. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
Choi IK; Kim BS; Lee KA; Ryu S; Seo HY; Sul H; Choi JG; Sung HJ; Park KH; Yoon SY; Oh SC; Seo JH; Choi CW; Shin SW; Yoon SY; Cho Y; Kim YK; Kim YH; Kim JS
Am J Hematol; 2004 Dec; 77(4):366-9. PubMed ID: 15551277
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
25. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.
Tefferi A; Pardanani A
Int J Hematol; 2004 Jun; 79(5):441-7. PubMed ID: 15239393
[TBL] [Abstract][Full Text] [Related]
26. Aggressive systemic mastocytosis: is there a role for trisomy 8?
Callera F; Chauffaille Mde L
Leuk Res; 2005 Apr; 29(4):471-3. PubMed ID: 15725484
[No Abstract] [Full Text] [Related]
27. Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate.
Boruban C; Sencan O; Akmansu M; Atik ET; Ozbek S
Anticancer Drugs; 2007 Sep; 18(8):969-72. PubMed ID: 17667604
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia.
Miyachi K; Ihara A; Hankins RW; Murai R; Maehiro S; Miyashita H
Clin Rheumatol; 2003 Oct; 22(4-5):329-32. PubMed ID: 14576993
[TBL] [Abstract][Full Text] [Related]
30. Systemic mastocytosis presenting with acute oliguric renal failure: report of a case and review of the literature.
Moore AE; Johnston WH; Hever A; Peng S; Kujubu DA
Int Urol Nephrol; 2012 Apr; 44(2):639-42. PubMed ID: 21110092
[TBL] [Abstract][Full Text] [Related]
31. Effects of imatinib mesylate on adenoid cystic carcinomas.
Ochel HJ; Gademann G; Röcken C; Wördehoff H
Anticancer Res; 2005; 25(5):3659-64. PubMed ID: 16101197
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
Bar-Sela G; Lev LM; Kuten A; Wollner M; Haim N
Harefuah; 2006 Jan; 145(1):2-7, 80. PubMed ID: 16450715
[TBL] [Abstract][Full Text] [Related]
33. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
[No Abstract] [Full Text] [Related]
34. Response of histiocytoses to imatinib mesylate: fire to ashes.
Janku F; Amin HM; Yang D; Garrido-Laguna I; Trent JC; Kurzrock R
J Clin Oncol; 2010 Nov; 28(31):e633-6. PubMed ID: 20733125
[No Abstract] [Full Text] [Related]
35. Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors?
Yoon SS; Tanabe KK
Ann Surg Oncol; 2007 Jun; 14(6):1784-6. PubMed ID: 17356951
[No Abstract] [Full Text] [Related]
36. Imatinib mesylate (STI571) for myeloid malignancies other than CML.
Krystal GW
Leuk Res; 2004 May; 28 Suppl 1():S53-9. PubMed ID: 15036942
[TBL] [Abstract][Full Text] [Related]
37. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
[TBL] [Abstract][Full Text] [Related]
38. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C
Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.
Gharibo M; Patrick-Miller L; Zheng L; Guensch L; Juvidian P; Poplin E
Pancreas; 2008 May; 36(4):341-5. PubMed ID: 18437079
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate.
Davey MP
Clin J Oncol Nurs; 2002; 6(2):118-20. PubMed ID: 11889677
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
